The Raynaud Phenomenon and Interferon Therapy
Authors: Andreas Creutzig
Journal: Annals of Internal Medicine (1996)

Letters1 September 1996The Raynaud Phenomenon and Interferon TherapyAndreas Creutzig, MD, Ludwig Caspary, MD, and Mathias Freund, MDAndreas Creutzig, MDMedizinische Hochschule, 30623 Hannover, GermanySearch for more papers by this author, Ludwig Caspary, MDMedizinische Hochschule, 30623 Hannover, GermanySearch for more papers by this author, and Mathias Freund, MDMedizinische Hochschule, 30623 Hannover, GermanySearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-125-5-199609010-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Interferon-α has been shown to prolong survival in patients with chronic myelogenous leukemia [1]. Long-term use of interferon-α has been linked to side effects related to autoimmune disease [2].We evaluated 9 women and 16 men (median age, 48 years; range, 24 to 74 years) with chronic-phase Ph1-positive myelogenous leukemia for episodes of the Raynaud phenomenon. Recombinant interferon-α 2b was administered for a median of 39 months (range, 10 to 73 months) at a median dosage of 30 million U/wk (range, 7 to 56 million U/wk).During interferon therapy, 13 patients (52%) reported symptoms typical of the ...References1. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-α for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet. 1995; 345:1392-7. Google Scholar2. Wandl UB, Nagel-Hiemke M, Kreuzfelder E, Kloke O, Kranzhoff M, Seeber S, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol. 1992; 65:70-4. Google Scholar3. Mahler F, Saner H, Boss C, Annaheim M. Local cold exposure test for capillaroscopic examination of patients with Raynaud's syndrome. Microvasc Res. 1987; 33:422-7. Google Scholar4. Ene L, Gehenot M, Horsmans Y, Detry-Morel M, Geubel AP. Transient blurred vision after interferon for chronic hepatitis C. Lancet. 1994; 344:827-8. Google Scholar5. Guyer DR, Tiedeman J, Yannuzzi L, Slakter JS, Parke D, Kelley J, et al. Interferon-associated retinopathy. Arch Ophthalmol. 1993; 111:350-6. Google Scholar Author, Article, and Disclosure InformationAuthors: Andreas Creutzig, MD; Ludwig Caspary, MD; Mathias Freund, MDAffiliations: Medizinische Hochschule, 30623 Hannover, Germany PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDrug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockersInterferon alfaDigital ischemic necrosis caused by pegylated interferon in a patient with hepatitis CCYTOKINES AND CYTOKINE MODULATORSANTIVIRAL DRUGS, INCLUDING IMMUNOGLOBULINS AND INTERFERONSEffets cutanéo-muqueux indésirables des cytokines et des nouvelles molécules anticancéreusesADVERSE CARDIOVASCULAR EFFECTS OF NON-CARDIOVASCULAR DRUGSVascular Toxicity of Antineoplastic AgentsInterferon alfaEffets cutanés indésirables des chimiothérapies antitumorales et des cytokinesLivedo reticularis associated with interferon alpha therapy in two melanoma patientsEfectos cutáneos adversos de la quimioterapia antineoplásica y de las citocinasVascular Events Associated with Alpha Interferon TherapyInterferon-α induced Raynaud's syndromeVasospastic SyndromeDiseases of the Blood VesselsSyndrome de Raynaud compliqué de gangrène digitale au cours d'un traitement par l'interféron alphaDrugs acting on the immune systemInterferon-??-2b-induced Raynaud's disease 1 September 1996Volume 125, Issue 5Page: 423KeywordsAntibodiesCapillariesChronic myelogenous leukemiaHeadachesInterferonsLesionsMicrohemorrhagesMicroscopySclerodermaVision ePublished: 15 August 2000 Issue Published: 1 September 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...